A Systematic Review of Factors Affecting Medication Adherence Among Patients with Osteoporosis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2018 Nov 13

PMID 30417253

Citations 84

Authors

C T Yeam

S Chia

H C C Tan

Y H Kwan

W Fong

J J B Seng

Affiliations

Soon will be listed here.

Abstract

Introduction: To identify factors that influence patients' adherence to anti-osteoporotic therapy.

Methods: A systematic review of literature was performed for articles published up till January 2018 using PubMed®, PsychINFO®, Embase®, and CINAHL®. Peer-reviewed articles which examined factors associated with anti-osteoporotic medication adherence were included. Classes of anti-osteoporotic therapy included bisphosphonates, parathyroid hormone-related analogue, denosumab, selective estrogen receptor modulators, estrogen/progestin therapy, calcitonin, and strontium ranelate. Meta-analyses, case reports/series, and other systematic reviews were excluded. Identified factors were classified using the World Health Organization's five dimensions of medication adherence (condition, patient, therapy, health-system, and socio-economic domains).

Results: Of 2404 articles reviewed, 124 relevant articles were identified. The prevalence of medication adherence ranged from 12.9 to 95.4%. Twenty-four factors with 139 sub-factors were identified. Bisphosphonates were the most well-studied class of medication (n = 59, 48%). Condition-related factors that were associated with poorer medication adherence included polypharmacy, and history of falls was associated with higher medication adherence. Patient-related factors which were associated with poorer medication adherence included older age and misconceptions about osteoporosis while therapy-related factors included higher dosing frequency and medication side effects. Health system-based factors associated with poorer medication adherence included care under different medical specialties and lack of patient education. Socio-economic-related factors associated with poorer medication adherence included current smoker and lack of medical insurance coverage.

Conclusion: This review identified factors associated with poor medication adherence among osteoporotic patients. To optimize therapeutic outcomes for patients, clinicians need to be aware of the complexity of factors affecting medication adherence.

Citing Articles

Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE.

Petersen T, Rubin K, Javaid M, Hermann A, Akesson K, Abrahamsen B Osteoporos Int. 2025; .

PMID: 39992408 DOI: 10.1007/s00198-025-07436-x.

A real-world analysis of 1,823 hospitalized osteoporotic fractures in Northeast China.

Meng Q, Wang X, Gao Y, Leslie W, Lix L, Shi X Front Endocrinol (Lausanne). 2025; 15():1520229.

PMID: 39839482 PMC: 11746098. DOI: 10.3389/fendo.2024.1520229.

Identifying and presenting key country-specific indicators related to medication adherence: a comprehensive study across European countries.

Agh T, Garuoliene K, Granas A, Gregorio J, Aksoy N, Khanyk N Front Pharmacol. 2024; 15:1390629.

PMID: 39431154 PMC: 11487323. DOI: 10.3389/fphar.2024.1390629.

Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease.

Sato A, Cregor M, McAndrews K, Schurman C, Schaible E, Shutter J JCI Insight. 2024; 9(21).

PMID: 39405125 PMC: 11601705. DOI: 10.1172/jci.insight.182664.

Examining the influence of anxiety and depression on medication adherence among patients diagnosed with acute myocardial infarction.

Ashour A, Masadeh R, Hamaideh S, Elshatarat R, Yacoub M, Almagharbeh W BMC Psychol. 2024; 12(1):473.

PMID: 39243104 PMC: 11378470. DOI: 10.1186/s40359-024-01959-4.

References

Gullberg B, Johnell O, Kanis J . World-wide projections for hip fracture. Osteoporos Int. 1997; 7(5):407-13. DOI: 10.1007/pl00004148. View

Clark E, Gould V, Tobias J, Horne R . Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study. Osteoporos Int. 2015; 27(2):579-90. DOI: 10.1007/s00198-015-3271-2. View

Erez H, Weller A, Vaisman N, Kreitler S . The relationship of depression, anxiety and stress with low bone mineral density in post-menopausal women. Arch Osteoporos. 2012; 7:247-55. DOI: 10.1007/s11657-012-0105-0. View

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

Ringe J, Christodoulakos G, Mellstrom D, Petto H, Nickelsen T, Marin F . Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin. 2007; 23(11):2677-87. DOI: 10.1185/03007x226357. View

Curtis J, Yun H, Matthews R, Saag K, Delzell E . Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken). 2012; 64(7):1054-60. PMC: 3355221. DOI: 10.1002/acr.21638. View

Penning-van Beest F, Goettsch W, Erkens J, Herings R . Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006; 28(2):236-42. DOI: 10.1016/j.clinthera.2006.01.002. View

Solomon D, Brookhart M, Tsao P, Sundaresan D, Andrade S, Mazor K . Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int. 2010; 22(6):1737-43. PMC: 4843120. DOI: 10.1007/s00198-010-1381-4. View

Klop C, Welsing P, Elders P, Overbeek J, Souverein P, Burden A . Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int. 2015; 26(6):1831-40. PMC: 4469296. DOI: 10.1007/s00198-015-3084-3. View

10.

Penning-van Beest F, Erkens J, Olson M, Herings R . Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008; 24(5):1337-44. DOI: 10.1185/030079908x297358. View

11.

Tomkova S, Telepkova D, Vanuga P, Killinger Z, Sulkova I, Celec P . Therapeutic adherence to osteoporosis treatment. Int J Clin Pharmacol Ther. 2014; 52(8):663-8. DOI: 10.5414/CP202072. View

12.

Ringe J, Moller G . Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. 2009; 30(2):213-21. DOI: 10.1007/s00296-009-0940-5. View

13.

Conti F, Piscitelli P, Italiano G, Parma A, Caffetti M, Giolli L . Adherence to Calcium and Vitamin D supplementations: results from the ADVICE Survey. Clin Cases Miner Bone Metab. 2013; 9(3):157-60. PMC: 3536003. View

14.

Curtis J, Westfall A, Cheng H, Lyles K, Saag K, Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008; 23(9):1435-41. PMC: 2574615. DOI: 10.1359/jbmr.080418. View

15.

Goldshtein I, Rouach V, Shamir-Stein N, Yu J, Chodick G . Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates. Adv Ther. 2016; 33(8):1374-84. DOI: 10.1007/s12325-016-0360-3. View

16.

Siris E, Steve Fan C, Yang X, Sajjan S, Sen S, Modi A . Association between gastrointestinal events and compliance with osteoporosis therapy. Bone Rep. 2017; 4:5-10. PMC: 4926838. DOI: 10.1016/j.bonr.2015.10.006. View

17.

Vytrisalova M, Blazkova S, Palicka V, Vlcek J, Cejkova M, Hala T . Self-reported compliance with osteoporosis medication-qualitative aspects and correlates. Maturitas. 2008; 60(3-4):223-9. DOI: 10.1016/j.maturitas.2008.07.009. View

18.

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006; 17(11):1645-52. DOI: 10.1007/s00198-006-0179-x. View

19.

Reynolds K, Muntner P, Cheetham T, Harrison T, Morisky D, Silverman S . Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int. 2013; 24(9):2509-17. DOI: 10.1007/s00198-013-2326-5. View

20.

Kyvernitakis I, Kostev K, Kurth A, Albert U, Hadji P . Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int. 2014; 25(12):2721-8. DOI: 10.1007/s00198-014-2810-6. View